Thyrocare Tech shares rally 19% as Q4 profit surges 25%, board recommends dividend; check key details

Shares of Thyrocare Technologies surged 18.66% on Thursday, April 24, to an intra-day high of ₹912.70 apiece on the National Stock Exchange (NSE), a day after it released its results for the quarter ending March 31, 2025.

At 2:10 PM, the stock was trading 11.52% higher at ₹857.80 per share.

For the fourth quarter of the 2024-25 financial year (Q4FY25), the company posted a 25.55% year-on-year (YoY) increase in its consolidated net profit to ₹21.57 crore as compared to ₹17.18 crore seen in the same quarter a year-ago period.

Thyrocare’s revenue from operations stood at ₹187.16 crore, jumping 21.34% YoY from ₹154.25 crore in the March quarter of the 2023-24 fiscal year (Q4FY24). The revenue from its pathology and radiology segments grew 23% YoY and 7% YoY, respectively.

Further, the company’s revenue from franchise increased by 22% YoY and partnership revenue was up by 24% YoY, Thyrocare said.

The Mumbai-based firm’s consolidated normalised EBITDA stood at ₹65.3 crore, surging 78% YoY from ₹36.7 crore. Its EBITDA margin was reported at 35% during the period under review, as against 24% in Q4FY24.

Thyrocare board recommends final dividend

The Board of Directors of Thyrocare Technologies recommended a final dividend of ₹21 per equity share for FY25, subject to the approval of the shareholders at the ensuing Annual General Meeting, the company said.

Appointment of Secretarial Auditor

Thyrocare’s board of directors also approved the appointment of Mehta & Mehta, Practicing Company Secretaries, as the company’s Secretarial Auditors, for five consecutive financial years from FY26 to FY30. This is subject to shareholder approval at the AGM.

Thyrocare Technologies stock performance

Shares of Thyrocare rose 20.90% over the past four days and 26.06% since the beginning of April. However, the scrip has lost 6.06% on a year-to-date basis.

The stock hit a 52-week high of ₹1,055 on January 5, 2025 and a low of ₹571.40 on June 4, 2024.

Thyrocare Technologies has a total market capitalisation of ₹4,540.74 crore as of April 24, 2025, on the NSE.